Sagimet Biosciences
A biopharmaceutical company developing therapeutics for the treatment of infectious diseases.
Launch date
Employees
Market cap
€109m
Enterprise valuation
(€42m) (Public information from Sep 2024)
Share price
$3.28 SGMT
San Mateo California (HQ)
Financials
Estimates*
| USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Revenues | - | - | - | 2.0m | - | - | - |
| EBITDA | (11.4m) | (23.7m) | (31.1m) | (30.7m) | - | - | - |
| % EBITDA margin | - | - | - | (1537 %) | - | - | - |
| Profit | (11.4m) | (24.4m) | (30.5m) | (27.9m) | (47.9m) | (119m) | (183m) |
| % profit margin | - | - | - | (1394 %) | - | - | - |
| EV / revenue | - | - | - | 14.6x | - | - | - |
| EV / EBITDA | - | - | - | -0.9x | - | - | - |
| R&D budget | 8.2m | 19.3m | 24.9m | 19.8m | - | - | - |
| R&D % of revenue | - | - | - | 989 % | - | - | - |
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
| N/A | $20.0m | Late VC | |
| N/A | $8.1m | Early VC | |
$20.0m | Series C | ||
$28.5m | Series D | ||
| N/A | $5.4m | Early VC | |
$18.0m | Series E | ||
$7.0m | Series E | ||
$80.0m | Late VC | ||
* | N/A | $96.4m | IPO |
* | N/A | $113m | Post IPO Equity |
| Total Funding | €204m | ||
Recent News about Sagimet Biosciences
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.